Last updated on September 2017

A phase 3, multi-center, randomized, placebo controlled, double-blind, study of the efficacy and safety of apremilast (CC-1004) in subjects with moderate to severe plaque psoriasis of the scalp.


Brief description of study

A phase 3, multi-center, randomized, placebo controlled, double-blind, study of the efficacy and safety of apremilast (CC-1004) in subjects with moderate to severe plaque psoriasis of the scalp.

Detailed Study Description

Otezla vs. Placebo for 16 weeks, 2:1
Open label week 16-32
4 week followup

Clinical Study Identifier: TX153238

Contact Investigators or Research Sites near you

Start Over

Jenna Spatz

Psoriasis Treatment Center of Central New Jersey
East Windsor, NJ USA
  Connect »